FDA Shopping For 3D Tissue Bioprinter, Cosmetic Contamination Testing Services
This article was originally published in The Rose Sheet
Executive Summary
Recent procurement activities show an agency increasingly focused on cosmetics’ safety vis-a-vis microbial threats and, in the case of talc-containing products, asbestos. Meanwhile, FDA seeks a 3D bioprinter to use in organ toxicity studies as an alternative to traditional animal models.
You may also be interested in...
Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.
Stakeholders Converge On California For Animal-Testing Bill Showdown
California lawmakers returning Aug. 6 from summer recess will have cosmetics industry reps and animal welfare groups vying for their ears, with the legislative clock ticking on a highly contentious proposal, SB 1249, to prohibit the sale of cosmetics containing ingredients tested “for any purpose” on animals.
FDA Analysis Of Non-Traditionally Preserved Cosmetics Indicates Likely Contamination Source
The agency’s survey of eye-area cosmetics marketed as free of traditional preservatives doesn’t raise any obvious red flags. However, it does point to a possible contamination source and suggests “the limits of preservative activity in cosmetics.”